Ketogenic Diets in the Management of Lennox-Gastaut Syndrome—Review of Literature

Urszula Skrobas * , Piotr Duda , Łukasz Bryliński , Paulina Drożak , Magdalena Pelczar and Konrad Rejdak

Department of Neurology, Medical University of Lublin, 20-090 Lublin, Poland
* Correspondence: urszula.skrobas@umlub.pl

Abstract: Epilepsy is an important medical problem with approximately 50 million patients globally. No more than 70% of epileptic patients will achieve seizure control after antiepileptic drugs, and several epileptic syndromes, including Lennox-Gastaut syndrome (LGS), are predisposed to more frequent pharmacoresistance. Ketogenic dietary therapies (KDTs) are a form of non-pharmacological treatments used in attempts to provide seizure control for LGS patients who experience pharmacoresistance. Our review aimed to evaluate the efficacy and practicalities concerning the use of KDTs in LGS. In general, KDTs are diets rich in fat and low in carbohydrates that put the organism into the state of ketosis. A classic ketogenic diet (cKD) is the best-evaluated KDT, while alternative KDTs, such as the medium-chain triglyceride diet (MCT), modified Atkins diet (MAD), and low glycemic index treatment (LGIT) present several advantages due to their better tolerability and easier administration. The literature reports regarding LGS suggest that KDTs can provide ≥50% seizure reduction and seizure-free status in a considerable percentage of the patients. The most commonly reported adverse effects are constipation, diarrhea, and vomiting, while severe adverse effects such as nephrolithiasis or osteopenia are rarely reported. The literature review suggests that KDTs can be applied safely and are effective in LGS treatment.

Keywords: epilepsy; epileptic syndromes; Lennox-Gastaut syndrome; diet therapy; ketogenic diets

1. Introduction

Epilepsy is a common neurological disease with approximately 50 million patients globally. Only fewer than 70% of epileptic patients can achieve seizure control with antiepileptic drugs [1]. There are certain syndromes in which that percentage is significantly lower, e.g., Lennox-Gastaut syndrome (LGS). LGS is a rare, severe, early-onset developmental epileptic encephalopathy characterized by a triad of multiple drug-resistant seizure types, a specific electroencephalography pattern showing bursts of slow spike-wave complexes or generalized paroxysmal fast activity, and intellectual impairment. Not all patients have all of the core seizure types (e.g., tonic, atonic, and atypical absences), especially at onset [2]. The tonic type of seizure is seen in all patients with LGS, but may not be present at the time of its onset [3]. The incidence of LGS is estimated at 0.1 to 0.28 per 100,000 people per year; the lifetime prevalence at the age of ten years amounts to 0.26 per 1000 children [4]. It is estimated that LGS patients account for 1–10% of cases of childhood epilepsy and 1–2% of all epilepsy patients [2]. There are identifiable and non-identifiable causes of LGS. Approximately, 65 to 75% of patients have an identifiable cause. These include brain damage (e.g., head injury), perinatal complications (e.g., birth asphyxia, intrauterine growth retardation, kernicterus), congenital central nervous system malformations (e.g., tuberous sclerosis), infections (e.g., meningitis, sepsis), or metabolic disorders [2,3]. When LGS has no apparent cause, a genetic predisposition or etiology is probable [2]. The mutation of genes involved in human brain development (e.g., the forkhead box G1 (FOXG1), or chromodomain-helicase-DNA-binding protein 2 (CHD2) genes) and the gene for presynaptic protein dynamin 1 (DNM 1) have been found to be
associated with this syndrome. Valproate, lamotrigine, and topiramate are considered the first-choice drugs. According to randomized control trials, other anti-epileptics reported to be effective are clobazam, felbamate, and rufinamide. It is important to start with as few drugs at a time as possible, in the lowest possible doses. If the first drug fails, change to another drug, but if the second drug is also not effective, a second agent can be added to the existing regimen [3]. As available pharmacologic treatments for seizures are limited in their efficacy, several non-pharmacological methods are used, including surgical and dietary interventions. Surgical procedures can lead to control in a select subset of patients suitable for that kind of treatment but still, a significant number of patients are left with uncontrolled seizures. The ketogenic diet and related diets have proven to be useful in drug-resistant childhood epilepsy [5]. The main purpose of this article is to evaluate the effectiveness and practicalities of using ketogenic dietary therapies (KDTs).

2. Search Strategy

A literature search was performed using PubMed keywords: “ketogenic diet”, “medium chain triglyceride diet”, “low glycemic index treatment”, “modified Atkins diet”, and “Lennox-Gastaut syndrome”. In this review, only publications in the English language were used. The efficacy of KDTs was determined by the percentage of patients that achieved at least 50% seizure reduction and seizure-free status.

3. Ketogenic Dietary Therapies

KDTs are well-established, nonpharmacological treatments used for children and adults with pharmacoresistant epilepsy [6]. Their mechanisms of action rely on putting the organism into a ketogenic state, similar to starvation, which has been reported as a treatment for epilepsy since ancient times [7]. KDT refers to any diet therapy in which dietary composition results in a ketogenic state of human metabolism. The diet generally refers to a high-fat, low-carbohydrate, and moderate-protein diet. Following the development of the classic ketogenic diet (cKD), new diets have been proposed in an attempt to increase retention and savoriness while imitating the effects produced by the original diet. Currently, there are four major KDTs—cKD, the modified Atkins diet (MAD), the medium-chain triglyceride diet (MCT), and the low glycemic index treatment (LGIT). The compositions of the four main KDTs differ (Table 1) and the data comparing the efficacy of the above-mentioned diets are limited [8].

The cKD and the MCT diet have been in existence the longest and are typically started in the hospital by a dietitian and neurologist. cKD is the oldest and the most researched diet among dietary therapies for epilepsy. It was designed in the year 1923 by doctor Russell Wilder from the Mayo Clinic and was designed to particularly treat this disease [9,10]. In the cKD, the fat source is largely long-chain triglycerides (LCT), which are gained mainly from standard foods. cKD is typically administered in a 4:1 ratio of fat to carbohydrate and protein, providing 90% of the total calories from the fat. MCT oils provide more ketones per kilocalorie of energy than LCTs. This enlarged ketogenic potential means less total fat is needed in the MCT diet, which allows the inclusion of more carbohydrates and protein and more potential food choices [6]. In both of the above-mentioned KDTs, calculations and arrangements concerning the diet and education of a patient and their family should be conducted by a dietitian [6,11].

As the cKD and MCT can be too restrictive, alternative diets were created. They are more liberal versions of the cKD, which are less restrictive on protein and calorie intake, more affordable for patients, and can be similarly effective in the treatment of epilepsy. The MAD was created at Johns Hopkins Hospital in 2003, primarily for children with behavioral difficulties and adolescents whose parents and neurologists were unwilling to start on the cKD [12]. The MAD is a high-fat, low-carbohydrate therapy which typically provides approximately a 1:1–1.5:1 ketogenic ratio, but no set ratio is required and some children can achieve a ratio as high as 4:1. The initial daily carbohydrate consumption on the MAD is approximately 10–15 g with a possible increase to 20 g per day after 1–3 months.
In addition, there is no restriction on protein, fluids, or calories, making meal planning easier. Detailed calculations are not required [6].

The LGIT was introduced as an elasticized version of the cKD and was first found to be successful in Massachusetts General Hospital in 2005 [13]. The diet is more liberal and allows 40 to 60 g of carbohydrates per day, but restricts sources of carbohydrates to a glycemic index of less than 50 to prevent postprandial increases in blood glucose. Fats and proteins are unrestricted. This diet is preferred by adolescents because of their difficulty in following the cKD. Admission to hospital is not required to implement the treatment [8].

| Ketogenic Diet Types                  | Components of the Major Ketogenic Diets                                                                 | References                                                                 |
|---------------------------------------|--------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------|
| Classic ketogenic diet (cKD) 4:1      | 4 g of fat to 1 g of protein plus carbohydrate                                                        | Zhang Y et al., 2016, [14]                                                 |
| Modified Atkins diet (MAD)            | not restricted, actively encouraged                                                                   | Sharma S et al., 2015, [15]                                               |
| Medium-chain triglyceride diet (MCT)  | 4.3 g/kg/d, of which 70% were MCT                                                                     | Rosenthal E et al., 1990, [16]                                            |
| Low glycemic index treatment (LGIT)   | 60% of total calories                                                                                  | Kim SH et al., 2017, [17]                                                 |

### 4. Mechanisms of KDTs’ Antiseizure Effect

Despite the antiseizure effect of ketosis being known from ancient times [7], the mechanisms of KDTs’ action have not been fully elucidated [18]. Among proposed theories, the abundance of ketone bodies (KBs) and fatty acids, the decreased glucose supply, and the impact on gut microbiota are mainly considered, inducing the modifications of neuronal metabolism, neurotransmitters, and ion channels [19–21]. Many authors suggest that the antiseizure effect of KDTs relies on a combination of several mechanisms [20,22–24].

KBs and fatty acids can generate direct changes in organism homeostasis. Acetoacetate [25] and beta-hydroxybutyrate [25,26] were shown to induce activation of ATP-sensitive potassium (KATP) channels [25,26], while polyunsaturated fatty acids (PUFA) and, presumably, KBs activate two-pore domain potassium (K2P) channels [27], increasing the seizure threshold via neuronal hyperpolarization [25–27]. A medium-chain fatty acid—decanoic acids—was shown to independently contribute to seizure control through alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor inhibition [23].

On the other hand, one of the first KBs-related hypotheses (the pH hypothesis) is no longer considered convincing, as some studies showed that KDTs do not make the blood nor brain tissue more acidic [28].

KDTs conditions also promote neuronal stability via their effects on the neurotransmitters mainly affecting gamma-aminobutyric acid (GABA) [19]. Uregulation of glutamic acid decarboxylase [29] and reduction in GABA transaminase activity [30] were suggested to result in enhanced GABA concentration. Regarding glutamate, the impact of KDTs on its levels is inconstant, and further research in this field is needed. Norepinephrine, dopamine, serotonin, galanine, and neuropeptide Y are highlighted among other neurotransmitters presumably involved in the antiseizure effect of KDTs [19].

Regarding energy metabolism, prolonged KDT implementation promotes mitochondria synthesis and concentration, increasing adenosine triphosphate (ATP) generation and enhancing the brain’s resistance to metabolic stress [19,28]. Reduced glycolysis presumably contributes to the antiseizure effect, as an intravenous glucose bolus reverses ketonemia and the antiseizure effects of KDTs rapidly [31]. Additionally, glucose restriction in KDTs promotes the pentose–phosphate pathway and is suspected to reduce reactive oxygen species (ROS)-dependent cell damage owing to enhanced nicotinamide adenine dinucleotide phosphate (NADPH) production [32].
Of late, the attention of researchers has focused on the KDTs’ impact on the microbiome–gut–brain axis. In an innovative study on two mice models, Olson et al. [33] showed that changes in gut microbiota were necessary for the antiseizure effects of KDTs, and the effect was mediated via elevating GABA/glutamate ratio in the hippocampus. Regarding humans, microbiome modification via probiotics was shown to promote seizure reduction [34], and several studies indicated that KDTs can alter the gut microbiome [21,35,36]. Some authors suggest that in the future, KDTs could even be replaced with prebiotic and probiotic supplementation or fecal microbial transplants (FMTs) [21].

5. Efficacy of cKD

The efficacy of cKD in the treatment of LGS is well-documented in scientific research. A literature review conducted by Lemmon ME et al. [37], which included 18 papers from the years 1989–2010 concerning applying cKD in, overall, 189 children with LGS, showed that after 3–36 months of using this diet, 47% of investigated children experienced ≥50% seizure reduction, whereas 16% of children achieved seizure-free status. Moreover, it was proven that the cKD causes a reduction in multiple types of epileptic seizures, including tonic, atonic, or atypical absence seizures. Additionally, a study conducted by Lemmon ME et al. showed that among 71 children who took part in the study, 32 (45%) were able to reduce the dose of parallelly taken anticonvulsant drugs while using cKD [37]. Reviewed papers from the years 2012–2020 show that a ≥50% seizure reduction was observed in 17–73% of patients, whereas a complete seizure reduction was observed in 1–23.5% of patients [6,14,37–41].

No predictive factors were found for the reduction in the number of seizures after using cKD in LGS. Research by Lemmon ME et al. [37] showed that age, gender, presence of side effects, etiology of LGS, number of previously taken anticonvulsants, and history of seizures during infancy were not predictive of >90% seizure reduction after 12 months of using cKD [37]. The reviewed data regarding the efficacy of cKD in the treatment of LGS is presented in Table 2.

![Table 2. Efficacy of classic ketogenic diet in Lennox-Gastaut syndrome.](image-url)
Table 2. Cont.

| Number of LGS Patients | Time of Assessment | Effectiveness (≥50% Seizure Reduction) | Effectiveness (Seizure-Free Status) | Side Effects | Additional Information | References |
|------------------------|--------------------|----------------------------------------|-----------------------------------|-------------|------------------------|------------|
|                        | 1 year 2 years     | 27.8% * 27.8% *                        | 11.1% * 11.1% *                   | Poor oral intake, metabolic acidosis, osteopenia, gastrointestinal problems, bleeding | The study involved patients with mitochondrial dysfunction. 16 patients were prescribed a KD with a lipid:nonlipid ratio of 4:1. Two patients were prescribed a KD with a lipid:nonlipid ratio of 3:1; the remaining two were prescribed the MAD (see Table 3) | Na JH et al., 2020, [41] |
|                        | 3rd month 6th month| 100% 100%                               | 0% 0%                             | The patient presented no side effects. | The study is a case report of a pediatric patients with tyrosinemia type 1. | De Lucia et al., 2015, [42] |

Abbreviations: LGS—Lennox-Gastaut syndrome; KD—ketogenic diet; MAD—modified Atkins diet; N/A—not available. *—quantity was calculated based on data from the publication.

6. Efficacy of Alternative Ketogenic Diets

Although alternative ketogenic diets were introduced to provide better tolerability and palatability than cKD, their efficacy is the most important issue. The comparison of the efficacy of MAD and cKD was assessed among the general population of children and adolescents with epilepsy. In a meta-analysis conducted by Razaee et al. [43], no statistically significant differences in efficacy were reported between MAD and cKD. Regarding LGS patients, a study conducted by Sharma S et al. [15] comprised of 25 pediatric LGS patients treated with MAD. After three months, nearly half of the patients had a ≥50% reduction in seizure frequency. After six months, 14 children discontinued the diet; however, all of the children who remained on the diet had more than a 50% reduction in seizure frequency both at the 6th and 12th month of the study [15]. In another retrospective study, Na JH et al. [41] assessed the efficacy of several KDTs in LGS patients, including two LGS patients who were prescribed MAD. One of the patients achieved 25% seizure reduction, while the second patient did not show any seizure reduction (Table 3) [41].

In another study by Kim et al. [17], LGIT was used as a treatment option on 36 epileptic patients. Only 12 patients had LGS and the rest of the patients had different epileptic syndromes. A positive response to prescribed treatment was seen in 75% (n = 9) of the LGS patients. The authors claimed that LGIT would be particularly effective among patients who previously responded favorably to cKD and could be a promising less-restrictive alternative after the success of cKD [17]. According to a case report by Kumada T et al. [44], LGIT allows for reducing the frequency of tonic seizures and myoclonic seizures. This case report described treatment using Japanese ethnic foods for a 13-year-old girl with LGS. At the age of 11 years, the patient was treated with MAD, but after two weeks she refused the diet. At the age of 13 years, LGIT was applied. After one year of therapy, the efficacy of the diet has been sustained (Table 3) [44].

According to a case report by Rosenthal E et al. [16], MCT served in parenteral nutrition provided the control of seizures and allowed normal daily functioning of one LGS patient. This case study shows that intravenous (iv) MCT can be used as a short-term method of maintaining ketosis for seizure control, but this method may be linked to complications (Table 3) [16].
Table 3. Efficacy of alternative ketogenic diets in Lennox-Gastaut syndrome.

| Number of LGS Patients | Ketogenic Diet Types | Time of Assessment | Effectiveness (≥50% Seizure Reduction) | Effectiveness (Seizure-Free) | Side Effects | Additional Information | References |
|------------------------|----------------------|--------------------|----------------------------------------|----------------------------|-------------|------------------------|------------|
| 25                     | MAD                  | 3rd month          | 48%                                    | 8% *                      | Constipation, vomiting, anorexia; | After a year 64% (n = 16) of the patients discontinued the KDT. | Sharma S et al., 2014, [15] |
|                        |                      | 6th month          | 44%                                    | 12% *                     |                          |                        |            |
|                        |                      | 12th month         | 36% *                                  | 12% *                     |                          |                        |            |
| 11                     |                      |                    |                                        |                           |                          |                        |            |
| 9                      |                      | 3rd month          | 0% *                                   | 0% *                      | Osteopenia               | One patient in the 3rd month of the MAD use had a 25% reduction rate of seizures. | Na JH et al., 2020, [41] |
|                        |                      | 6th month          | 0% *                                   | 0% *                      |                          |                        |            |
|                        |                      | 9th month          | 0% *                                   | 0% *                      |                          |                        |            |
|                        |                      | 12th month         | 0% *                                   | 0% *                      |                          |                        |            |
|                        |                      | 24th month         | 0% *                                   | 0% *                      |                          |                        |            |
| 2                      | MAD                  |                    |                                        |                           |                          |                        |            |
| 1                      | LGIT                 | 12 months          | N/A                                    | N/A                       | N/A                      | After 1 month, the tonic seizures during sleep had decreased to a frequency of once or twice per month. | Kumada T et al., 2013, [44] |
|                        |                      |                    |                                        |                           |                          |                        |            |
| 12                     | LGIT                 | 3rd month          | N/A                                    | N/A                       | Transient diarrhea, laboratory abnormalities—reduced serum total carbon dioxide, hypercholesterolemia, increased alanine aminotransferase, increased lipase, increased blood urea nitrogen; | 75% of patients with LGS had a positive response to LGIT. | Kim, SH et al., 2017, [17] |
|                        |                      | 6th month          | N/A                                    | N/A                       |                          |                        |            |
|                        |                      | 12th month         | N/A                                    | N/A                       |                          |                        |            |
| 1                      | parenteral MCT       | 6 months           | N/A                                    | N/A                       | Abnormal liver function tests and severe iron deficiency anemia, increased levels of serum triglyceride and cholesterol | Intravenous nutrition was applied because oral feeding and nasogastric and nasoduodenal feeding were precluded. | Rosenthal E et al., 1990, [16] |

Abbreviations: LGS—Lennox-Gastaut syndrome; KDT—ketogenic dietary therapy; MAD—modified Atkins diet; N/A—not available; LGIT—low glycemic index treatment; MCT—medium-chain triglyceride diet. *—quantity was calculated based on data from the publication.

7. Safety and Tolerability of Ketogenic Dietary Therapies

The literature reports from the general epileptic population show that KDTs are generally considered as safe treatment options [40,41,45]. They are applied in adults, as well as in children [46], showing good tolerability for patients as young as six weeks [47]. Additionally, cKD may be used in groups of LGS patients presenting certain metabolic abnormalities. A study conducted by Na et al. [41] suggests that KDTs can be used to treat LGS in patients with mitochondrial dysfunction, while De Lucia et al. [42] suggested that cKD with restricted phenylalanine and tyrosine can be used in patients with tyrosinemia type 1. In addition, van der Louw et al. [48] showed the case series of two pregnant women with epilepsy. One was treated with MCT as a monotherapy, while the second was treated with MAD and lamotrigine. Both women achieved seizure reduction, and, after labor, their children presented normal growth and development at a follow-up of 12 and 8 months, respectively. On the other hand, the child of the second woman presented bilateral ear deformities of unknown significance. The authors claimed that KDTs may be effective during pregnancy, but their safety has to be established [48]. Common adverse effects of KDs are vomiting, constipation, and diarrhea [40,49]. However, in the meta-analysis of randomized controlled trials, the above-mentioned adverse effects were also commonly
reported by the patients from the usual-care group with diets having no known effects on epilepsy [49].

In the case of LGS, reviewed research papers show that the use of cKD could have certain side effects including gastrointestinal disturbances, such as diarrhea, constipation or vomiting, hypocalcemia, kidney stones, hyperuricemia, and metabolic acidosis [50]. Patients subjected to cKD also experience problems with the cardiovascular system, kidneys, and skeletal system [51]. Moreover, research shows that this diet could cause growth retardation in children [52,53]; however, the data regarding growth retardation is mixed [6]. It was proven that patients who experience side effects have a higher risk of non-adherence to this diet [49].

Compared to cKD, a lower occurrence of side effects is an advantage of LGIT. As a result, this diet is reported as easier to use and continue [19,44]. The side effect among all patients in one of the reported studies was transient diarrhea. In addition, laboratory abnormalities were observed—reduced serum total carbon dioxide, hypercholesterolemia, increased alanine aminotransferase, increased lipase, and increased blood urea nitrogen. However, mentioned conditions did not require additional management or medication [17].

Similarly, MCT, which enables higher carbohydrate and protein, seems to be more favorable and palatable for children than the cKD [5,19]. However, the authors of the case study concerning iv MCT stated that this method had complications—abnormal liver function tests and severe iron deficiency anemia of unknown etiology. In addition, serum triglyceride and cholesterol levels increased, but they decreased after a reduction in lipid infusion and the use of an antihyperlipidemic drug [16].

In the reviewed studies concerning MAD, patients reported mild side effects including constipation, vomiting, and anorexia. In addition, none of the children from that study had serious side effects, such as deranged renal or hepatic functions [15]. On the other hand, the authors of the second MAD publication reported that one of the patients showed osteopenia as a side effect of the diet [41]. However, MAD is better tolerated by patients than the cKD and they are more willing to follow MAD (56%) than cKD (38%) [54]. MAD also presents several advantages regarding patient comfort and benefits for the healthcare system. There is no need for hospitalization during dietary treatment onset. Lower costs of the diet and better tolerability suggest that MAD may be a promising substitute for patients who do not tolerate cKD well. These aspects are even more significant in some regions of the world, where no KD centers are available [43].

8. Problem of Attrition

A high attrition rate of patients receiving KDTs is still a major concern among the general epileptic population [43,49]. The most frequently reported reasons for cKD discontinuation are a lack of expected efficacy [14,49,55], dietary intolerance and strictness [20,55], and its low palatability [17,49]. However, the authors of the meta-analysis of randomized controlled trials regarding KDTs reported no statistically significant differences in attrition rates between the KDs group and the usual care group, with attrition rates of 8–38% and 2.5–32%, respectively [49]. Similarly to reports from general epileptic patients, the most frequent discontinuation reason in reviewed publications was a lack of effectiveness, both for the cKD [56] and MAD [15].

9. Conclusions

According to the authors of the above-mentioned studies, KDTs are effective in LGS treatment. KDTs are reported as safe treatment options and can be administered to different populations of epileptic patients. The most common complications include constipation, diarrhea, and vomiting, while severe adverse effects are rarely reported. Several less-restrictive KDTs, including MCT, MAD, and LGIT, are worth considering, due to their better tolerability, lower treatment costs, and easier administration.
10. Future Directions

As many of the studies comprise small patient samples, further large randomized controlled trials would be needed to clarify the issue of KDTs efficacy. What is more, future studies should address the issues of patients’ quality of life and cognitive outcomes more frequently, and more consistency in reporting seizure reduction rates (e.g., based on ≥50% seizure reduction rates, and seizure-free status rates) would be beneficial. The paucity of studies concerning adults and infants indicates the need to evaluate these patient populations, particularly.

Author Contributions: Conceptualization, P.D. (Piotr Duda); methodology, M.P. and P.D. (Paulina Droźak); formal analysis, U.S. and K.R.; investigation, P.D. (Piotr Duda), Ł.B., P.D. (Paulina Droźak) and M.P.; resources, L.B., P.D. (Paulina Droźak) and M.P.; writing—original draft preparation, P.D. (Piotr Duda), Ł.B., P.D. (Paulina Droźak) and M.P.; writing—review and editing, P.D. (Piotr Duda), Ł.B., P.D. (Paulina Droźak) and M.P.; visualization, L.B., P.D. (Paulina Droźak) and M.P.; supervision, U.S. and K.R.; project administration, P.D. (Piotr Duda), U.S. and K.R.; funding acquisition, K.R. All authors have read and agreed to the published version of the manuscript.

Funding: This research received no external funding.

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Data Availability Statement: Not applicable.

Acknowledgments: We would like to sincerely thank Ruth Atinda for assistance with the English-language correcting.

Conflicts of Interest: The authors declare no conflict of interest.

Abbreviations

AMPA Alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid  
ATP Adenosine triphosphate  
cKD Classic ketogenic diet  
CHD2 Chromodomain-helicase-DNA-binding protein 2  
DNM1 Presynaptic protein dynamin 1  
EEG Electroencephalography  
FMT Fecal microbial transplant  
FOXG1 The forkhead box G1  
GABA Gamma-aminobutyric acid  
KDTs Ketogenic dietary therapies  
LGIT Low-glycemic index treatment  
LGS Lennox-Gastaut syndrome  
MAD Modified Atkins diet  
MCT Medium-chain triglyceride diet  
ROS Reactive oxygen species

References

1. Epilepsy. Available online: https://www.who.int/en/news-room/fact-sheets/detail/epilepsy (accessed on 23 February 2022).
2. Asadi-Pooya, A.A. Lennox-Gastaut Syndrome: A Comprehensive Review. Neurol. Sci. 2018, 39, 403–414. [CrossRef] [PubMed]
3. Jahngir, M.U.; Ahmad, M.Q.; Jahangir, M. Lennox-Gastaut Syndrome: In a Nutshell. Cureus 2018, 10, e3134. [CrossRef] [PubMed]
4. Orphanet: Lennox Gastaut Syndrome. Available online: https://www.orpha.net/consor/www/cgi-bin/OC_Exp.php?lng=EN&Expert=2382 (accessed on 9 May 2022).
5. Winesett, S.P.; Bessone, S.K.; Kossoff, E.H.W. The Ketogenic Diet in Pharmacoresistant Childhood Epilepsy. Expert Rev. Neurother. 2015, 15, 621–628. [CrossRef] [PubMed]
6. Kossoff, E.H.; Zupec-Kania, B.A.; Auvin, S.; Ballaban-Gil, K.R.; Christina Bergqvist, A.G.; Blackford, R.; Buchhalter, J.R.; Caraballo, R.H.; Cross, J.H.; Dahlin, M.G.; et al. Optimal Clinical Management of Children Receiving Dietary Therapies for Epilepsy: Updated Recommendations of the International Ketogenic Diet Study Group. Epilepsia Open 2018, 3, 175–192. [CrossRef] [PubMed]
7. Wheless, J.W. History of the Ketogenic Diet. Epilepsia 2008, 49, 3–5. [CrossRef] [PubMed]
8. Wells, J.; Swaminathan, A.; Paseka, J.; Hanson, C. Efficacy and Safety of a Ketogenic Diet in Children and Adolescents with Refractory Epilepsy-A Review. Nutrients 2020, 12, 1809. [CrossRef] [PubMed]
9. Pinto, A.; Bonucci, A.; Maggi, E.; Corsi, M.; Businaro, R. Anti-Oxidant and Anti-Inflammatory Activity of Ketogenic Diet: New Perspectives for Neuroprotection in Alzheimer’s Disease. Antioxidants 2018, 7, 63. [CrossRef] [PubMed]
10. Misiewicz Runyon, A.; So, T.-Y. The Use of Ketogenic Diet in Pediatric Patients with Epilepsy. ISRN Pediatr. 2012, 2012, 263139. [CrossRef]
11. Pfeifer, H.H.; Lyczkowski, D.A.; Thiele, E.A. Low Glycemic Index Treatment: Implementation and New Insights into Efficacy. Epilepsia 2008, 49 (Suppl. 58), 42–45. [CrossRef] [PubMed]
12. Kossoff, E.H.; Dorward, J.L. The Modified Atkins Diet. Epilepsia 2008, 49, 37–41. [CrossRef]
13. Fiebig, H.H.; Thiele, E.A. Low-Glycemic-Index Treatment: A Liberalized Ketogenic Diet for Treatment of Intractable Epilepsy. Neurology 2005, 65, 1810–1812. [PubMed]
14. Zhang, Y.; Wang, Y.; Zhou, Y.; Zhang, L.; Yu, L.; Zhou, S. Therapeutic Effects of the Ketogenic Diet in Children with Lennox-Gastaut Syndrome. Epilepsy Res. 2016, 128, 176–180. [CrossRef] [PubMed]
15. Sharma, S.; Jain, P.; Gatl, S.; Sankhyan, N.; Agarwala, A. Use of the Modified Atkins Diet in Lennox Gastaut Syndrome. J. Child Neurol. 2015, 30, 576–579. [CrossRef] [PubMed]
16. Rosenthal, E.; Weissman, B.; Kyllonen, K. Use of Parenteral Medium-Chain Triglyceride Emulsion for Maintaining Seizure Control in a 5-Year-Old Girl with Intractable Drarrrhea. J. Parenter. Enter. Nutr. 1990, 14, 543–545. [CrossRef]
17. Kim, S.H.; Kang, H.C.; Lee, E.J.; Lee, J.S.; Kim, H.D. Low Glycemic Index Treatment in Patients with Drug-Resistant Epilepsy. Brain Dev. 2017, 39, 687–692. [CrossRef] [PubMed]
18. Fan, Y.; Wang, H.; Liu, X.; Zhang, J.; Liu, G. Crossstalk between the Ketogenic Diet and Epilepsy: From the Perspective of Gut Microbiota. Mediat. Inflamm. 2019, 2019, 8373060. [CrossRef] [PubMed]
19. Barzegar, M.; Afghan, M.; Tarmahi, V.; Behtari, M.; Rahimi Khamaneh, S.; Raeisi, S. Ketogenic Diet: Overview, Types, and Possible Anti-Seizure Mechanisms. Nutr. Neurosci. 2021, 24, 307–316. [CrossRef] [PubMed]
20. D’Andrea Meira, I.; Romão, T.T.; Do Prado, H.J.P.; Krüger, L.T.; Pires, M.E.P.; Da Conceição, M. Ketogenic Diet and Protective Mechanisms in Epilepsy, Metabolic Disorders, Cancer, Neuronal Loss, and Muscle and Nerve Degeneration. J. Neurosci. Res. 2021, 12, 742449. [CrossRef] [PubMed]
21. Lindefeldt, M.; Eng, A.; Darban, H.; Bjerkner, A.; Zetterström, C.K.; Allander, T.; Andersson, B.; Borenstein, E.; Dahlin, M.; Prast-Nielsen, S. The Ketogenic Diet Influences Taxonomic and Functional Composition of the Gut Microbiota in Children with Severe Epilepsy. NPJ Biofilms Microbiomes 2019, 5, 5. [CrossRef] [PubMed]
22. Youngson, N.A.; Morris, M.J.; Ballard, B. The Mechanisms Mediating the Antiepileptic Effects of the Ketogenic Diet, and Potential Opportunities for Improvement with Metabolism-Altering Drugs. Seizure 2017, 52, 15–19. [CrossRef]
23. Boison, D. New Insights into the Mechanisms of the Ketogenic Diet. Curr. Opin. Neurol. 2017, 30, 187–192. [CrossRef]
24. Ding, M.; Lang, Y.; Shu, H.; Shao, J.; Cui, L. Microbiota-Gut-Brain Axis and Epilepsy: A Review on Mechanisms and Potential Therapeutics. Front. Immunol. 2021, 12, 742449. [CrossRef] [PubMed]
25. Yellen, G. Ketone Bodies, Glycolysis, and KATP Channels in the Mechanism of the Ketogenic Diet. Nutrients 2008, 49, 80. [CrossRef] [PubMed]
26. Tanner, G.R.; Lutas, A.; Martínez-François, J.R.; Yellen, G. Single K-ATP Channel Opening in Response to Action Potential Firing in Mouse Dentate Granule Neurons. J. Neurosci. 2011, 31, 8689–8696. [CrossRef] [PubMed]
27. Vamecq, J.; Valée, L.; Lesage, F.; Gressens, P.; Stables, J.P. Antiepileptic Popular Ketogenic Diet: Emerging Twists in an Ancient Story. Prog. Neurobiol. 2005, 75, 1–28. [CrossRef]
28. Nylen, K.; Liljedii, S.; Burnham, W.M.I. The Ketogenic Diet: Proposed Mechanisms of Action. Neurotherapeutics 2009, 6, 402. [PubMed]
29. Cheng, C.M.; Hicks, K.; Wang, J.; Eagles, D.A.; Bondy, C.A. Caloric Restriction Augments Brain Glutamic Acid Decarboxylase-65 and -67 Expression. J. Neurosci. Res. 2004, 77, 270–276. [CrossRef]
30. Suzuki, Y.; Takahashi, H.; Fukuda, M.; Hino, H.; Kobayashi, K.; Tanaka, J.; Ishii, E. Beta-Hydroxybutyrate Alters GABA-Transaminase Activity in Cultured Astrocytes. Brain Res. 2009, 1268, 17–23. [CrossRef]
31. Huttonlocher, P.R. Ketogenic and Seizures: Metabolic and Anticonvulsant Effects of Two Ketogenic Diets in Childhood Epilepsy. Pediatr. Res. 1976, 10, 536–540. [CrossRef] [PubMed]
32. Li, R.J.; Liu, Y.; Liu, H.Q.; Li, J. Ketogenic Diets and Protective Mechanisms in Epilepsy, Metabolic Disorders, Cancer, Neuronal Loss, and Muscle and Nerve Degeneration. J. Food Biochem. 2020, 44, e13140. [CrossRef]
33. Olson, C.A.; Vuong, H.E.; Yano, J.M.; Liang, Q.Y.; Nusbaum, D.J.; Hsiao, E.Y. The Gut Microbiota Mediates the Anti-Seizure Effects of the Ketogenic Diet. Cell 2018, 173, 1728–1741.e13. [CrossRef]
34. Gómez-Eguilaz, M.; Ramón-Trapero, J.L.; Pérez-Martínez, L.; Blanco, J.R. The Beneficial Effect of Probiotics as a Supplementary Treatment in Drug-Resistant Epilepsy: A Pilot Study. Benef. Microbes 2018, 9, 875–881. [CrossRef] [PubMed]
35. Xie, G.; Zhou, Q.; Qiu, C.Z.; Dai, W.K.; Wang, H.P.; Li, Y.H.; Liao, J.X.; Lu, X.G.; Lin, S.F.; Ye, J.H.; et al. Ketogenic Diet Poses a Significant Effect on IMbalanced Gut Microbiota in Infants with Refractory Epilepsy. World J. Gastroenterol. 2017, 23, 6164–6171. [CrossRef] [PubMed]
36. Zhang, Y.; Zhou, S.; Zhou, Y.; Yu, L.; Zhang, L.; Wang, Y. Altered Gut Microbiome Composition in Children with Refractory Epilepsy after Ketogenic Diet. Epilepsy Res. 2018, 145, 163–168. [CrossRef]
37. Lemmon, M.E.; Terao, N.N.; Ng, Y.T.; Reisig, W.; Rubenstein, J.E.; Kossoff, E.H. Efficacy of the Ketogenic Diet in Lennox-Gastaut Syndrome: A Retrospective Review of One Institution’s Experience and Summary of the Literature. *Dev. Med. Child Neurol.* **2012**, *54*, 464–468. [CrossRef]

38. Caraballo, R.H.; Fortini, S.; Fresler, S.; Armento, M.; Ariela, A.; Cresta, A.; Mestre, G.; Escobal, N. Ketogenic Diet in Patients with Lennox-Gastaut Syndrome. *Seizure* **2014**, *23*, 751–755. [CrossRef]

39. Kim, H.J.; Kim, H.D.; Lee, J.S.; Heo, K.; Kim, D.S.; Kang, H.C. Long-Term Prognosis of Patients with Lennox-Gastaut Syndrome in Recent Decades. *Epilepsy Res.* **2015**, *110*, 10–19. [CrossRef] [PubMed]

40. Wu, Q.; Wang, H.; Fan, Y.Y.; Zhang, J.M.; Liu, X.Y.; Fang, X.Y.; Yang, F.H.; Cao, Q.J.; Qi, Y. Ketogenic Diet Effects on 52 Children with Pharmacoresistant Epileptic Encephalopathy: A Clinical Prospective Study. *Brain Behav.* **2018**, *8*, e00973. [CrossRef]

41. Na, J.H.; Kim, H.D.; Lee, Y.M. Effective and Safe Diet Therapies for Lennox-Gastaut Syndrome with Mitochondrial Dysfunction. *Ther. Adv. Neurol. Disord.* **2020**, *13*, 1–12. [CrossRef]

42. De Lucia, S.; Fichard, S.; Ilea, A.; Grenache, M.O.; Francois, L.; Delanoë, C.; Schiff, M.; Auvin, S. An Unfortunate Challenge: Ketogenic Diet for the Treatment of Lennox-Gastaut Syndrome in Tyrosinemia Type 1. *Eur. J. Paediatr. Neurol.* **2016**, *20*, 674–677. [CrossRef]

43. Rezaei, S.; Abdurahman, A.A.; Saghazadeh, A.; Badv, R.S.; Mahmoudi, M. Short-Term and Long-Term Efficacy of Classical Ketogenic Diet and Modified Atkins Diet in Children and Adolescents with Epilepsy: A Systematic Review and Meta-Analysis. *Nutr. Neurosci.* **2019**, *22*, 317–334. [CrossRef]

44. Kumada, T.; Hiejima, I.; Nozaki, F.; Hayashi, A.; Fujii, T. Glycemic Index Treatment Using Japanese Foods in a Girl with Lennox-Gastaut Syndrome. *Pediatr. Neurol.* **2014**, *48*, 390–392. [CrossRef]

45. Sharawat, I.K.; Panda, P.K.P.; Sihag, R.K.; Panda, P.K.P.; Dawman, L. Efficacy and Safety of Corpus Callosotomy and Ketogenic Diet in Children with Lennox Gastaut Syndrome: A Systematic Review and Meta-Analysis. *Childs Nerv. Syst.* **2021**, *37*, 2557–2566. [CrossRef] [PubMed]

46. Williams, T.J.; Cervenka, M.C. The Role for Ketogenic Diets in Epilepsy and Status Epilepticus in Adults. *Clin. Neurophysiol. Pract.* **2017**, *2*, 154–160. [CrossRef]

47. Thompson, L.; Fecske, E.; Salim, M.; Hall, A. Use of the Ketogenic Diet in the Neonatal Intensive Care Unit-Safety and Tolerability. *Epilepsia* **2017**, *58*, e36–e39. [CrossRef]

48. van der Louw, E.J.T.M.; Williams, T.J.; Henry-Barron, B.J.; Olieman, J.F.; Duvekot, J.J.; Vermeulen, M.J.; Bannink, N.; Williams, M.; Neuteboom, R.F.; Kossoff, E.H.; et al. Ketogenic Diet Therapy for Epilepsy during Pregnancy: A Case Series. *Seizure* **2017**, *45*, 198–201. [CrossRef] [PubMed]

49. Martin-McGill, K.J.; Bresnahan, R.; Levy, R.G.; Cooper, P.N. Ketogenic Diets for Drug-Resistant Epilepsy; John Wiley and Sons Ltd.: Hoboken, NJ, USA, 2020; Volume 2020. Volume 2020.

50. Azevedo de Lima, P.; Baldini Prudêncio, M.; Murakami, D.K.; Pereira de Brito Sampaio, L.; Figueiredo Neto, A.M.; Teixeira Damasceno, N.R. Effect of Classic Ketogenic Diet Treatment on Lipoprotein Subfractions in Children and Adolescents with Refractory Epilepsy. *Nutrition* **2017**, *33*, 271–277. [CrossRef] [PubMed]

51. Cai, Q.-Y.; Zhou, Z.-J.; Luo, R.; Gan, J.; Li, S.-P.; Mu, D.-Z.; Wan, C.-M. Safety and Tolerability of the Ketogenic Diet Used for the Treatment of Refractory Childhood Epilepsy: A Systematic Review of Published Prospective Studies. *World J. Pediatr.* **2017**, *13*, 528–536. [CrossRef]

52. Ferraris, C.; Guglielmetti, M.; Pasca, L.; De Giorgis, V.; Ferraro, O.E.; Brambilla, I.; Leone, A.; De Amicis, R.; Bertoli, S.; Veggiiotti, P.; et al. Impact of the Ketogenic Diet on Linear Growth in Children: A Single-Center Retrospective Analysis of 34 Cases. *Nutrients* **2019**, *11*, 1442. [CrossRef] [PubMed]

53. Bertoli, S.; Masnada, S.; De Amicis, R.; Sangiorgio, A.; Leone, A.; Gambino, M.; Lessa, C.; Tagliabue, A.; Ferraris, C.; De Giorgis, V.; et al. Glucose Transporter 1 Deficiency Syndrome: Nutritional and Growth Pattern Phenotypes at Diagnosis. *Eur. J. Clin. Nutr.* **2020**, *74*, 1290–1298. [CrossRef] [PubMed]

54. Samanta, D. Management of Lennox-Gastaut Syndrome beyond Childhood: A Comprehensive Review. *Epilepsy Behav.* **2021**, *114*, 107612. [CrossRef] [PubMed]

55. Ruan, Y.; Chen, L.; She, D.; Chung, Y.; Ge, L.; Han, L. Ketogenic Diet for Epilepsy: An Overview of Systematic Review and Meta-Analysis. *Eur. J. Clin. Nutr.* **2022**, *76*, 1234–1244. [CrossRef] [PubMed]

56. Vehmeijer, F.O.L.; van der Louw, E.J.T.M.; Arts, W.F.M.; Catsman-Berrevoets, C.E.; Neuteboom, R.F. Can We Predict Efficacy of the Ketogenic Diet in Children with Refractory Epilepsy? *Eur. J. Paediatr. Neurol.* **2015**, *19*, 701–705. [CrossRef] [PubMed]